Answers are grounded in this paper and cite their sources.
Background/Objectives: Resistance to cancer therapy is attributed to the tumour microenvironment, not to tumour-cell genotype alone. Pyroptosis, the gasdermin-executed lytic death programme triggered mainly by NLRP3, is oncosuppressive in one compartment and resistance-promoting in another. We resolve that divergence by compartment and place brain-derived neurotrophic factor (BDNF) upstream. Methods: Narrative, mechanism-oriented review. Four queries covering the sensor, pyroptotic execution, malignancy and BDNF were screened on title and abstract; retained sources measured at least one step of the cascade, and claims were graded. Results: Acute activation in neoplastic cells releases damage-associated molecular patterns and supports immunogenic cell death, whereas chronic sublytic activation in M2-polarised tumour-associated macrophages sustains interleukin-1β/18 signalling, regulatory T-cell and myeloid-derived suppressor cell expansion, angiogenesis and checkpoint-blockade failure. BDNF restrains inflammasome activation in non-neoplastic systems through nuclear factor-κB priming, mitophagy, KLF2-dependent restraint of hexokinase 1, membrane repair and necroptosis crosstalk; no study has measured BDNF, NLRP3 and pyroptotic execution together in a tumour. Conclusions: We propose that BDNF may set this threshold in tumours, and a four-type classification by BDNF and NLRP3 status to organise experiment, not treatment. It makes compartment, duration and repair capacity, not the pathway's presence, decide whether pyroptotic signalling favours or defeats therapy, and specifies what would falsify it.
No takes yet. Share an insight, caveat, or question.
Coradduzza et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: